Annals of Hematology

, 88:67

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

  • Ulrike Klein
  • Florentina Kosely
  • Jens Hillengaß
  • Michael Hundemer
  • Stefan Schmitt
  • Kai Neben
  • Thomas Moehler
  • Ute Hegenbart
  • Anthony D. Ho
  • Hartmut Goldschmidt
Original Article

Abstract

The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM). Their efficacy is increased with the addition of dexamethasone, but significant rates of venous thromboembolism (VTE) are a severe side effect. Based on this evidence, it is recommended that VTE prophylaxis be prescribed in these patients. However, the optimal prophylaxis remains controversial. We analyzed 45 patients with relapsed MM who were treated with lenalidomide and dexamethasone at our center. The 45 patients received a total number of 192 cycles, respectively a median of three cycles; the median dosage of dexamethasone was 240 mg per cycle. All patients received prophylactic anticoagulation with low molecular weight heparin (LMWH). Moreover, 86.6% of patients had at least one additional VTE risk factor beside the myeloma-related risk. One out of 45 patients developed a deep vein thrombosis and pulmonary embolism. None of the other 44 patients had clinical signs of thrombosis or embolism and none of all patients experienced complications or side effects due to anticoagulation. Our results indicate that prophylactic anticoagulation with LMWH is safe and effective. Therefore, we propose LMWH should be used in patients being treated with lenalidomide and dexamethasone at least for the first 3 months of treatment until randomized trials have proven the equality of other pharmacological prophylaxis.

Keywords

IMiDs Lenalidomide Low molecular weight heparin Multiple myeloma Prophylaxis Thrombosis 

References

  1. 1.
    Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8(4):381–388 doi:10.1634/theoncologist.8-4-381 PubMedCrossRefGoogle Scholar
  2. 2.
    Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351(9109):1077–1080 doi:10.1016/S0140-6736(97)10018-6 PubMedCrossRefGoogle Scholar
  3. 3.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722 doi:10.1001/jama.293.6.715 PubMedCrossRefGoogle Scholar
  4. 4.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1):16–19 doi:10.1200/JCO.2003.03.139 PubMedCrossRefGoogle Scholar
  5. 5.
    Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8(11):3377–3382PubMedGoogle Scholar
  6. 6.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med 160(6):809–815 doi:10.1001/archinte.160.6.809 PubMedCrossRefGoogle Scholar
  7. 7.
    Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5):1614–1615 doi:10.1182/blood.V98.5.1614 PubMedCrossRefGoogle Scholar
  8. 8.
    Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133–2142 doi:10.1056/NEJMoa070596 PubMedCrossRefGoogle Scholar
  9. 9.
    Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080 doi:10.1056/NEJMc053530 PubMedCrossRefGoogle Scholar
  10. 10.
    Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080 doi:10.1056/NEJMc053530 PubMedCrossRefGoogle Scholar
  11. 11.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132 doi:10.1056/NEJMoa070594 PubMedCrossRefGoogle Scholar
  12. 12.
    Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF et al Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. ASH Annual Meeting Abstracts 2007 November 16;110(11):77Google Scholar
  13. 13.
    Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M (2006) Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4(8):1842–1845 doi:10.1111/j.1538-7836.2006.02059.x PubMedCrossRefGoogle Scholar
  14. 14.
    Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 2007 November 16;110(11):74Google Scholar
  15. 15.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159(5):445–453 doi:10.1001/archinte.159.5.445 PubMedCrossRefGoogle Scholar
  16. 16.
    Palumbo A, Cavo M, Bringhen S, Perrone G, Magarotto V, Patriarca F, et al Prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. ASH Annual Meeting Abstracts 2007 November 16;110(11):310.Google Scholar
  17. 17.
    Wright JA, Weber D, Thomas SK, Wang M, Alexanian R, Hawkins VE, et al Characteristics of patients experiencing thromboembolic events during treatment for multiple myeloma: aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors. ASH Annual Meeting Abstracts 2007 November 16;110(11):1882Google Scholar
  18. 18.
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San MJ, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423 doi:10.1038/sj.leu.2405062 PubMedCrossRefGoogle Scholar
  19. 19.
    Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10):3557–3560 doi:10.1182/blood-2006-08-036947 PubMedCrossRefGoogle Scholar
  20. 20.
    Durie BGM, Richardson P, Palumbo A, Dimopoulos MA, Cavo M, Hajek R et al (2006) Deep vein thrombosis in myeloma: estimate of prevalence and recommendations for therapy based upon a survey of members of the International Myeloma Working Group (IMWG). Blood 108(11):3571 ASH Annual Meeting AbstractsGoogle Scholar
  21. 21.
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl 3):338S–400S doi:10.1378/chest.126.3_suppl.338S PubMedCrossRefGoogle Scholar
  22. 22.
    Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1568–1574PubMedCrossRefGoogle Scholar
  23. 23.
    Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505 doi:10.1200/JCO.2007.14.1283 PubMedCrossRefGoogle Scholar
  24. 24.
    Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AMW, Westveer PHM, Sonneveld P, Goldschmidt H, Lokhorst HM (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18(12):2044–2046 doi:10.1038/sj.leu.2403533 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Ulrike Klein
    • 1
  • Florentina Kosely
    • 1
  • Jens Hillengaß
    • 1
  • Michael Hundemer
    • 1
  • Stefan Schmitt
    • 1
  • Kai Neben
    • 1
  • Thomas Moehler
    • 1
  • Ute Hegenbart
    • 1
  • Anthony D. Ho
    • 1
  • Hartmut Goldschmidt
    • 1
    • 2
  1. 1.Department of Internal Medicine VUniversity of HeidelbergHeidelbergGermany
  2. 2.National Center for Tumor Diseases HeidelbergHeidelbergGermany

Personalised recommendations